The FDA approved a labeling update for axicabtagene ciloleucel (Yescarta), removing the prior contraindication for treating primary CNS lymphoma after data and regulatory review. The change follows research and regulatory submissions that addressed safety and efficacy in CNS disease, and it allows clinicians to consider a CD19‑directed CAR‑T for patients previously excluded. The decision expands the approved clinical setting for an established CAR‑T therapy and may influence trial design and treatment pathways for CNS lymphoma.